Response Genetics, Inc

Equities

RGDXQ

US76123U1051

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:32:09 2023-05-15 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2016	Response Genetics, Inc Bankruptcy Case Dismissed	CI
2016	Motion for Case Dismissal Filed for Response Genetics, Inc	CI

Response Genetics, Inc. Launches New and Innovative Non-Small Cell Lung Cancer Profile

September 15, 2014 at 07:00 am EDT

Response Genetics Inc. announced it has launched a new and innovative Non-Small Cell Lung Cancer Profile that merges rapid turnaround on National Comprehensive Cancer Network (NCCN) guideline markers with next-generation sequencing (NGS). This new reflex, or sequential, testing program offers oncologists and pathologists a cost-effective way to utilize comprehensive cancer testing, including NGS, as a reflex-testing option for those patients who test negative for EGFR, ALK and ROS1, the biomarkers recommended by the NCCN.

Latest news about Response Genetics, Inc

Response Genetics, Inc Bankruptcy Case Dismissed	16-04-18	CI
Motion for Case Dismissal Filed for Response Genetics, Inc	16-03-22	CI
Response Genetics, Inc Announces Resignation of David Wurzer as Non-Executive Director	15-11-20	CI
Response Genetics, Inc Announces Board Changes	15-10-14	CI
Cancer Genetics, Inc. completed the acquisition of substantially all the assets and operations of Response Genetics, Inc.	15-10-08	CI
Motion for Asset Sale Approved for Response Genetics, Inc	15-10-01	CI
Notice for Auction Cancellation Filed by Response Genetics, Inc	15-09-28	CI
Final DIP Financing Approved for Response Genetics, Inc	15-09-08	CI
Bidding Procedure Approved for Response Genetics, Inc	15-08-28	CI
Motion for Asset Sale Filed by Response Genetics, Inc	15-08-14	CI
Response Genetics, Inc will Change its Ticker to RGDX.Q from RGDX	15-08-11	CI
Interim DIP Financing Approved for Response Genetics, Inc	15-08-11	CI
Cancer Genetics, Inc. entered into an agreement to acquire substantially all the assets and operations from Response Genetics, Inc for $13.8 million.	15-08-09	CI
Response Genetics, Inc Filed for Bankruptcy	15-08-09	CI
Response Genetics, Inc(OTCPK:RGDX) dropped from NASDAQ Composite Index	15-07-19	CI
Greece and China expose limits of 'whatever it takes'	15-07-08	RE
Response Genetics, Inc(OTCPK:RGDX.Q) dropped from S&P TMI Index	15-07-08	CI
Response Genetics, Inc(OTCPK:RGDX.Q) dropped from CRSP US Total Market Index	15-07-07	CI
Response Genetics, Inc(OTCPK:RGDX.Q) dropped from MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	15-07-07	CI
Response Genetics, Inc. Enters into a Third Amendment to its Credit Agreement	15-07-01	CI
Response Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	15-05-14	CI
Response Genetics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014	15-03-31	CI
Response Genetics, Inc Auditor Raises 'Going Concern' Doubt	15-03-30	CI
Response Genetics, Inc Announces Resignation of Stephanie H. Astrow as Vice President, Research and Development	15-03-20	CI
Response Genetics, Inc. Enters into First Amendment to Credit Agreement	15-02-06	CI

Chart Response Genetics, Inc

Duration

Period

More charts

Company Profile

Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RESPONSE GENETICS, INC	-.--%	38
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research